Comparative Pharmacology
Head-to-head clinical analysis: GLYXAMBI versus INVOKANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLYXAMBI versus INVOKANA.
GLYXAMBI vs INVOKANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GLYXAMBI is a combination of empagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Empagliflozin reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin increases incretin hormones (GLP-1, GIP), enhancing insulin release and decreasing glucagon levels in a glucose-dependent manner.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor; reduces renal glucose reabsorption, increasing urinary glucose excretion.
10 mg/5 mg orally once daily (empagliflozin/linagliptin). May increase to 25 mg/5 mg once daily if tolerated.
100 mg orally once daily, before the first meal of the day; may increase to 300 mg once daily if tolerated and eGFR is adequate.
None Documented
None Documented
Empagliflozin: Terminal half-life ~12.4 hours allows once-daily dosing. Linagliptin: Terminal half-life >100 hours, but pharmacodynamic effect correlates with DPP-4 inhibition rather than plasma levels.
Terminal elimination half-life is 10.6 hours (range 9.5–12.5 h) in healthy subjects; allows once-daily dosing. Half-life increases to 16 hours in moderate renal impairment and 22 hours in severe renal impairment.
Empagliflozin: Approximately 95.6% excreted in feces (41.2% as unchanged drug) and 54.4% in urine (19.8% as unchanged). Linagliptin: 84% excreted in feces via enterohepatic circulation (80% as parent drug) and 5% in urine.
Primarily excreted unchanged in urine (33%) and feces (52%) as parent drug and glucuronide metabolites; renal clearance accounts for 70% of total clearance, with 51% renally excreted as unchanged drug.
Category C
Category C
SGLT2 Inhibitor/DPP-4 Inhibitor Combination Antidiabetic
SGLT2 Inhibitor